Skip to content

Clinical trial of needle-free injection system

Needle-free system for insulin injection in a multicenter, prospective, randomized, self-controlled cross-sectional clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065064
Enrollment
Unknown
Registered
2022-10-27
Start date
2020-08-23
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

experiment group:Insulin was injected subcutaneously with the experimental needle-free injection system
control group:Control needle - free injection system was used with hypodermic injection of insulin

Sponsors

Jiangxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with diabetes requiring subcutaneous insulin injection. 2. Ages 18 to 75, regardless of gender. 3. 18 kg/m^2 = 8 weeks at the time of screening. 6. Voluntarily participate in the clinical trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Injection site infection. 2. Patients with severe bleeding or severe disorders of bleeding or coagulation (International Normalized Ratio (INR) > 2.5) or platelets below 50*10^9/L. 3. Patients with severe anemia and hemoglobin disorders (hemoglobin less than 60 g/L). 4. Patients with severe liver and kidney function abnormalities (for laboratory test indicators exceeding two times the upper limit of the reference range). 5. Patients who are pregnant, lactating and have recent childbirth plans. 6. Patients with severe cardiovascular diseases (unstable myocardial infarction, cerebral infarction, unstable angina pectoris, severe arrhythmias). 7. Patients with malignant tumors. 8. Patients without the ability to express themselves verbally; patients with impaired consciousness. 9. Patients with mental illness or medical history. 10. Patients who, in the opinion of the investigator, are not suitable to participate in this clinical trial. 11. Patients who participated in other clinical trials within the month prior to enrollment.

Design outcomes

Primary

MeasureTime frame
AUC of serum insulin concentration within 3 hours after breakfast;

Secondary

MeasureTime frame
Area under the blood glucose concentration curve 3 hours after breakfast;Compliance of needle-free injection systems;

Countries

China

Contacts

Public ContactJiangdong Liu

Jiangxi Provincial People's Hospital

jmjxnc@163.com+86 13037200789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026